Multiple Sclerosis Treatment Becomes Canada’s First MS Stem Cell Clinical Trial.

The University of Ottawa trial infuses MSCs to reduce inflammation in the central nervous systems of MS patients.

The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading

Burn Treatment Replaces Skin Grafts with Stem Cells.

Stem cells may eliminate the need for painful skin grafts for burn victims.

In a new two year clinical trial conducted by the University of Miami, researchers will attempt to treat deep second degree burn victims with mesenchymal stem cells [MSCs] as a potential alternative to skin grafts.  The team, led by Dr. Evangelos Badiavas, will first cover the wounds in protective dressing, and then inject the MSCs under the dressing and into the wounds to spur the regeneration of the inner and outer layers of skin.

Severe burns currently account for 450,000 emergency room treatments annually, as well as 15-20% of combat injuries to military veterans.  But despite a high demand to eliminate painful and taxing skin graft surgeries, they are currently the only option for reconstruction.  While Dr. Badiavas’ stem cell therapy is in its initial assessment phase, early indications point to  possible MSC treatments that may  provide a more comfortable and efficient method to regenerate healthy skin tissue, resulting in better outcomes for patients.

As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.

 

 

To view the full article, click here.

 

 

The Future of Regenerative Medicine is Now™

Hypoplastic Left Heart Syndrome Treatment Integrates Cardiac Stem Cells.

Initial trials of stem cell treatment for hypoplastic left heart syndrome have proven to be both safe and effective for children with the congenital defect.

Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell.  In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading

Atherosclerotic Lesions Prevented by MSCs

Stem cells were found to reduce plaque in patients with atherosclerosis.

According to new research from the National Yang-Ming University, mesenchymal stem cells [MSCs] hold the ability to limit atherosclerotic plaque formation, thereby preventing the onset of harmful endothelial lesions. The research team, led by Shih-Chieh Hung, transplanted MSCs into animal models with atherosclerosis and observed significant reduction in plaque formation. They also saw an increase in blood vessel dilation, which prevents further plaque development, indicating good endothelial health. Continue reading

Multiple Sclerosis Trial Exhibits Positive Results of Stem Cell Therapy.

A five year phase II clinical trial has shown initial success in treating multiple sclerosis.

In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations.  The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading

Bone Regeneration Technique Stimulates Stem Cells with Magnetic Nanoparticles.

Remote controlled nanoparticles may allow stem cells to regenerate bone tissue

Medical researchers from Keele University and Nottingham University have integrated remote controlled magnetic nanoparticles to incite the differentiation of stem cells into new bone tissue for the treatment of bone diseases, disorders, and injuries. In pre-clinical trials, the nanoparticles were coated with proteins that stimulate the stem cells, and then delivered directly to the damaged tissue via an external magnetic field. Continue reading

Game, Set, Match: Tennis Elbow Gets Aced by Stem Cell Therapy

In a new pilot study at the Royal National Orthopaedic Hospital in London, researchers will utilize stem cells to promote the healing of painful tendon injuries such as tennis elbow.  Initial studies suggest that, upon transplantation, the stem cells release growth factors to the point of injury, which induce the growth of new tendon tissue while reducing scar tissue to recover movement and flexibility. Continue reading

Lupus Therapy Incorporates Mesenchymal Stem Cells

Beijing researchers are capitalizing on the abilities of mesenchymal stem cells to reduce inflammation and promote cell growth to combat systemic lupus erythematosus.

In a recent clinical study conducted in Beijing, researchers are testing a treatment for patients suffering from systemic lupus erythematosus by administering autologous [the patient’s own] mesenchymal stem cells.  The researchers aim to capitalize on the unique abilities of MSCs to not only differentiate into a multitude of different cell types, but to reduce the autoimmune attack in patients affected by lupus as well. Continue reading

Multiple Sclerosis Therapy Incorporates Stem Cells in Clinical Trial

Mesenchymal Stem Cell Therapy has been deemed safe for patients suffering from multiple sclerosis.

A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans.  27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection. Continue reading

Multiple Sclerosis Therapy Incorporates Stem Cells in Clinical Trial

Mesenchymal Stem Cell Therapy has been deemed safe for patients suffering from multiple sclerosis.

A recent clinical trial conducted by the University of Genoa has determined that mesenchymal stem cell therapy to treat multiple sclerosis is indeed safe to perform on humans.  27 MS patients completed the study, which comprised an injection of the patient’s own [autologous] mesenchymal stem cells [MSCs] to reduce excessive inflammation caused by the patients’ own immune systems. None of the patients suffered any side effects from the injection. Continue reading